Glivec.com - Common Questions about Glivec GIST and CML for HCPs

About Glivec

Target: CML

Target: GIST

Rare Diseases

For Your Patients

GIPAP

Common Patient Questions

References

News and Events

Resources

European Summary of Product Characteristics

Haematology and Oncology News from Glivec.com

Our weekly newsletter keeps you informed of the latest haematology and oncology news.

Help us improve Glivec.com.
Please take our short survey.

Print Glivec Information from Novartis Oncology

1 2 3

The following questions will help you prepare to respond to typical patient concerns and queries about Glivec^® (imatinib) and its role in CML (chronic myeloid leukaemia) and GIST (gastrointestinal stromal tumour) treatment.

1. Frequently Asked Questions in CML

a.Questions About CML
b.Questions About Glivec^® (imatinib) in CML

2. Frequently Asked Questions in GIST

a.Questions About GIST
b.Questions About Glivec in GIST

GIPAP is open in about 80 countries.As of November 30, 2007 the total number of patients reached was 19,378.

Disclaimer: This is an international website for Glivec (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.